創美藥業(02289.HK)獲江西江中醫藥商業運營提收購要約 明日復牌
格隆匯9月28日丨創美藥業(02289.HK)公吿，轉讓人(公司控股股東、董事會主席、執行董事及集團行政總裁、要約人一致行動集團成員姚創龍先生)已吿知董事會，轉讓人和要約人江西江中醫藥商業運營有限責任公司於2022年9月13日簽訂了《股份轉讓協議》。
在《股份轉讓協議》的條款及條件規限下，轉讓人有條件同意出售而要約人有條件同意購買出售股份，即公司全部已發行股本的9.00%，總對價為7086萬港元，即每股出售股份為7.29港元。
交割完成之時，要約人將收購或控制公司約39.60%的表決權。要約人及其各一致行動方將擁有合計7330萬股股份，佔公司於本聯合公吿發布之日全部已發行股本的67.87%。
根據《收購守則》規則26.1，於交割完成之時，將要求要約人對所有已發行股份提出無條件強制性現金要約。每股要約股份7.29港元現金，較於最後交易日在聯交所所報的每股7.40港元收市價約1.49%的折讓。
要約人是一家在中國成立的有限責任公司，主要開展藥品的批發和零售業務，以及食品、消毒設備和三類醫療器械的銷售業務。作為一家江西省國有企業，其20.50%的股份由江西省國有資本運營控股集團有限公司持有，而該公司最終由江西省國有資產監督管理委員會控制；20.50%的股份由華潤江中製藥集團有限責任公司持有，而該公司最終由在香港聯交所主板上市(股份代號：3320.hk)的華潤醫藥集團有限公司控制；16.80%的股份由樟樹市興浩企業諮詢服務中心(有限合夥)持有；10.20%的股份由南昌市眾合醫藥管理中心(有限合夥)持有；9.80%的股份由南昌市眾誠醫藥管理中心(有限合夥)持有。
要約人擬繼續從事集團的業務，並繼續僱用集團的運營和行政僱員。於本聯合公吿發布之日，要約人概無意向或計劃收購或處置集團的資產和/或業務。但是，在要約交割完成之後，要約人將詳細審查集團的經營，制定實際可行的業務策略，以期制定可持續公司戰略，擴大收入來源，可能包括在適當時機重新平衡集團的資源。
要約人擬維持公司的上市地位，並將承諾，確保根據《上市規則》規則8.08維持股份的充足公眾持股量。
此外，公司已申請自2022年9月29日上午9：00起在香港聯交所恢復股份交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
